BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 20685720)

  • 1. Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas.
    Pérez-Magán E; Rodríguez de Lope A; Ribalta T; Ruano Y; Campos-Martín Y; Pérez-Bautista G; García JF; García-Claver A; Fiaño C; Hernández-Moneo JL; Mollejo M; Meléndez B
    Neuro Oncol; 2010 Dec; 12(12):1278-90. PubMed ID: 20685720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic changes with prognostic value in histologically benign meningiomas.
    Barbera S; San Miguel T; Gil-Benso R; Muñoz-Hidalgo L; Roldan P; Gonzalez-Darder J; Cerda-Nicolas M; Lopez-Gines C
    Clin Neuropathol; 2013; 32(4):311-7. PubMed ID: 23442303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: diagnostic and prognostic implications.
    Cai DX; Banerjee R; Scheithauer BW; Lohse CM; Kleinschmidt-Demasters BK; Perry A
    J Neuropathol Exp Neurol; 2001 Jun; 60(6):628-36. PubMed ID: 11398839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of 1p and 14q status, MIB-1 labeling index and progesterone receptor immunoexpression in meningiomas: Adjuncts to histopathological grading and predictors of aggressive behavior.
    Kumar S; Kakkar A; Suri V; Kumar A; Bhagat U; Sharma MC; Singh M; Suri A; Sarkar C
    Neurol India; 2014; 62(4):376-82. PubMed ID: 25237942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Her2neu amplification associates with Co-deletion 1p/14q in recurrent meningiomas.
    Hamilton BO; Sy JS; Megyesi JF; Ang LC
    Can J Neurol Sci; 2013 May; 40(3):361-5. PubMed ID: 23603172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence.
    Menghi F; Orzan FN; Eoli M; Farinotti M; Maderna E; Pisati F; Bianchessi D; Valletta L; Lodrini S; Galli G; Anghileri E; Pellegatta S; Pollo B; Finocchiaro G
    Oncologist; 2011; 16(10):1440-50. PubMed ID: 21948653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic alterations associated with progression and recurrence in meningiomas.
    Pérez-Magán E; Campos-Martín Y; Mur P; Fiaño C; Ribalta T; García JF; Rey JA; Rodríguez de Lope A; Mollejo M; Meléndez B
    J Neuropathol Exp Neurol; 2012 Oct; 71(10):882-93. PubMed ID: 22964784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and prognostic significance of genetic regional heterogeneity in meningiomas.
    Pfisterer WK; Hank NC; Preul MC; Hendricks WP; Pueschel J; Coons SW; Scheck AC
    Neuro Oncol; 2004 Oct; 6(4):290-9. PubMed ID: 15494096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular biological determinations of meningioma progression and recurrence.
    Linsler S; Kraemer D; Driess C; Oertel J; Kammers K; Rahnenführer J; Ketter R; Urbschat S
    PLoS One; 2014; 9(4):e94987. PubMed ID: 24722350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
    Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
    Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profiles of metabolic aggressiveness and tumor recurrence in benign meningioma.
    Serna E; Morales JM; Mata M; Gonzalez-Darder J; San Miguel T; Gil-Benso R; Lopez-Gines C; Cerda-Nicolas M; Monleon D
    PLoS One; 2013; 8(6):e67291. PubMed ID: 23840654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence-associated chromosomal anomalies in meningiomas: Single-institution study and a systematic review with meta-analysis.
    Och W; Szmuda T; Sikorska B; Springer J; Jaskólski D; Zakrzewska M; Liberski PP
    Neurol Neurochir Pol; 2016; 50(6):439-448. PubMed ID: 27575681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor grade-related NDRG2 gene expression in primary and recurrent intracranial meningiomas.
    Skiriute D; Tamasauskas S; Asmoniene V; Saferis V; Skauminas K; Deltuva V; Tamasauskas A
    J Neurooncol; 2011 Mar; 102(1):89-94. PubMed ID: 20607352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings.
    Al-Mefty O; Kadri PA; Pravdenkova S; Sawyer JR; Stangeby C; Husain M
    J Neurosurg; 2004 Aug; 101(2):210-8. PubMed ID: 15309910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone.
    Maillo A; Orfao A; Espinosa AB; Sayagués JM; Merino M; Sousa P; Lara M; Tabernero MD
    Neuro Oncol; 2007 Oct; 9(4):438-46. PubMed ID: 17704362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas.
    Lamszus K; Kluwe L; Matschke J; Meissner H; Laas R; Westphal M
    Cancer Genet Cytogenet; 1999 Apr; 110(2):103-10. PubMed ID: 10214357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1p/14q co-deletion: A determinant of recurrence in histologically benign meningiomas.
    Kakkar A; Kumar A; Das A; Pathak P; Sharma MC; Singh M; Suri A; Sarkar C; Suri V
    Indian J Pathol Microbiol; 2015; 58(4):433-8. PubMed ID: 26549062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of material from chromosome arm 1p during malignant progression of meningioma revealed by fluorescent in situ hybridization.
    Ishino S; Hashimoto N; Fushiki S; Date K; Mori T; Fujimoto M; Nakagawa Y; Ueda S; Abe T; Inazawa J
    Cancer; 1998 Jul; 83(2):360-6. PubMed ID: 9669820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade.
    Schmidt M; Mock A; Jungk C; Sahm F; Ull AT; Warta R; Lamszus K; Gousias K; Ketter R; Roesch S; Rapp C; Schefzyk S; Urbschat S; Lahrmann B; Kessler AF; Löhr M; Senft C; Grabe N; Reuss D; Beckhove P; Westphal M; von Deimling A; Unterberg A; Simon M; Herold-Mende C
    Oncotarget; 2016 Mar; 7(12):14551-68. PubMed ID: 26894859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrative genomic analysis identifies CCNB1 and CDC2 as candidate genes associated with meningioma recurrence.
    Bie L; Zhao G; Ju Y; Zhang B
    Cancer Genet; 2011 Oct; 204(10):536-40. PubMed ID: 22137483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.